Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema for the Treatment of Type 2 Diabetes Mellitus: A Bayesian Network Meta Analysis Journal of Clinical Question PDF) Eloralintide, a selective, longacting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48 week phase 2, multicentre, double blind, randomised, placebo controlled trial The Lancet Amylin based therapies are emerging as promising obesity medications. , Eloralintide is a novel, selective amylin receptor agonist in development for weight management, type 2 diabetes and more! , The evolving landscape of obesity pharmacotherapy Nature Reviews Drug Discovery, 2026 1 Obesity pharmacotherapy has moved from weight loss drugs to cardiometabolic disease modifying therapy Obesity is now framed as a chronic, relapsing, Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept ScienceDirect